Is the third generation EGFR TKIs the solution for making EGFR mutant NSCLC a curable disease?

Autor Hirsch, Fred R.
Vydáno v Transl Lung Cancer Res (2014)

The TOPICAL study should be more topical!

Autor Hirsch, Fred R.
Vydáno v Transl Lung Cancer Res (2013)

Clinical potential of necitumumab in non-small cell lung carcinoma

Autor Genova, Carlo, Hirsch, Fred R
Vydáno v Onco Targets Ther (2016)

PACIFIC trial: new perspectives for immunotherapy in lung cancer

Autor Agustoni, Francesco, Hirsch, Fred R.
Vydáno v Transl Lung Cancer Res (2018)

Clinical and comparative utility of afatinib in non-small cell lung cancer

Autor D’Arcangelo, Manolo, Hirsch, Fred R
Vydáno 2014

“COMPANION DIAGNOSTICS”: Has their time come and gone?

Autor Hirsch, Fred R., Bunn, Paul A., Herbst, Roy S
Vydáno 2014

Sniffing the Unique “Odor Print” of Non-Small-Cell Lung Cancer with Gold Nanoparticles

Autor Barash, Orna, Peled, Nir, Hirsch, Fred R., Haick, Hossam
Vydáno 2009

Is there clinical value to prognostic signatures in early stage NSCLC?

Autor Bunn, Paul A., Hirsch, Fred R., Aisner, Dara L.
Vydáno 2014

From Mice to Men and back – an assessment of preclinical model systems for the study of lung cancers

Autor Gazdar, Adi F., Hirsch, Fred R., Minna, John D.
Vydáno v J Thorac Oncol (2015)

Potential future consideration for imaging and blood-based biomarkers for precision medicine in lung cancer

Autor Kong, Feng-Ming (Spring), Hirsch, Fred R., Machtay, Mitchell
Vydáno v Transl Lung Cancer Res (2017)

Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer

Autor Peled, Nir, Yoshida, Koichi, Wynes, Murry W., Hirsch, Fred R.
Vydáno 2009

Heterogeneity in Tumors and Resistance to EGFR TKI Therapy—Letter

Autor Suda, Kenichi, Rivard, Christopher J., Mitsudomi, Tetsuya, Hirsch, Fred R.
Vydáno v Cancer Res (2016)

ROS1 Immunohistochemistry Among Major Genotypes of Non—Small-Cell Lung Cancer

Autor Boyle, Theresa A., Masago, Katsuhiro, Ellison, Kim E., Yatabe, Yasushi, Hirsch, Fred R.
Vydáno v Clin Lung Cancer (2014)

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench

Autor Suda, Kenichi, Bunn, Paul A., Rivard, Christopher J., Mitsudomi, Tetsuya, Hirsch, Fred R.
Vydáno v J Thorac Oncol (2016)

PD-L1 Expression in Lung Cancer

Autor Yu, Hui, Boyle, Theresa A., Zhou, Caicun, Rimm, David L., Hirsch, Fred R.
Vydáno v J Thorac Oncol (2016)

sLAG-3 in non-small-cell lung cancer patients’ serum

Autor He, Yayi, Wang, Yan, Zhao, Sha, Zhao, Chao, Zhou, Caicun, Hirsch, Fred R
Vydáno v Onco Targets Ther (2018)

Serum microRNAs improving the diagnostic accuracy in lung cancer presenting with pulmonary nodules

Autor He, Yayi, Ren, Shengxiang, Wang, Yan, Li, Xuefei, Zhou, Caicun, Hirsch, Fred R.
Vydáno v J Thorac Dis (2018)

TIM-3, a promising target for cancer immunotherapy

Autor He, Yayi, Cao, Jie, Zhao, Chao, Li, Xuefei, Zhou, Caicun, Hirsch, Fred R
Vydáno v Onco Targets Ther (2018)

Treatment of spine metastases in cancer: a review

Autor Chen, Yu, He, Yayi, Zhao, Chao, Li, Xuefei, Zhou, Caicun, Hirsch, Fred R
Vydáno v J Int Med Res (2019)

Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819

Autor Redman, Mary W., Crowley, John J., Herbst, Roy S., Hirsch, Fred R., Gandara, David R.
Vydáno 2012